Understand the source comparison
Peptides Help with Athletic Performance: Full Comparison
Growth Hormone-Releasing Peptides (CJC-1295, Ipamorelin, GHRP-2) Stimulate pituitary GH secretion via ghrelin receptor activation Increased IGF-1 levels, improved recovery, enhanced body composition 100–200 mcg subcutaneously before morning cardio or sleep, on
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth Hormone-Releasing Peptides (CJC-1295, Ipamorelin, GHRP-2)
- Stimulate pituitary GH secretion via ghrelin receptor activation
- Increased IGF-1 levels, improved recovery, enhanced body composition
- 100–200 mcg subcutaneously before morning cardio or sleep, on empty stomach
- Human clinical trials show 200–300% increase in 24-hour GH secretion; IGF-1 elevation documented in controlled studies
- Strongest evidence base among performance peptides. Mechanism well-characterized, dose-response relationship established, side effect profile favorable compared to exogenous GH
- Tissue Repair Peptides (BPC-157, TB-500)
- Local acceleration of angiogenesis, fibroblast migration, and collagen synthesis at injury sites
- Faster recovery from tendon, ligament, and muscle injuries; reduced re-injury risk
- BPC-157: 250–500 mcg subcutaneously daily; TB-500: 2–5 mg twice weekly for 4–6 weeks
- Strong animal model data; human evidence limited to case reports and observational studies
- Mechanistically plausible with compelling preclinical evidence, but lack of controlled human trials limits definitive efficacy claims. Widely used in sports medicine despite evidence gap
- Anti-Inflammatory Peptides (KPV)
- Selective NF-κB inhibition in immune cells, reducing pro-inflammatory cytokine production
- Management of overtraining-related systemic inflammation without blunting acute training adaptation
- 500 mcg subcutaneously daily for 2–4 weeks during high-stress training blocks
- In vitro and animal studies demonstrate selective anti-inflammatory action; human performance data minimal
- Novel mechanism with theoretical advantages over NSAIDs, but human performance trials needed to establish efficacy and optimal dosing
- Immune Modulation Peptides (Thymalin)
- Restoration of thymic T-cell production and immune surveillance function
- Reduced infection incidence during heavy training; faster recovery from illness
- 10 mg intramuscularly twice weekly during high-volume phases
- Clinical use in immunodeficiency contexts; performance application extrapolated from immune function studies
- Well-established immune benefits in clinical populations; performance application logical but lacks sport-specific validation